- Home
- KRKR vs BCAB Comparison
KRKR vs BCAB Comparison
Compare KRKR & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRKR | BCAB |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 7.5M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KRKR | BCAB |
|---|---|---|
| Price | $3.50 | $4.39 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.0K | ★ 30.1K |
| Earning Date | 03-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.87 | $0.12 |
| 52 Week High | $21.36 | $6.52 |
Technical Indicators
Market Signals| Indicator | KRKR | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 54.57 |
| Support Level | $3.11 | $0.36 |
| Resistance Level | $5.09 | $5.18 |
| Average True Range (ATR) | 0.42 | 0.42 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 32.53 | 37.30 |
Price Performance
Historical ComparisonAbout KRKR 36Kr Holdings Inc.
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in the PRC.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.